Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome

Psychoneuroendocrinology

Volumn 37, Issue 4, 2012, Pages 509-518

  Hall, Scott S ^a   Lightbody, Amy A ^a   McCarthy, Brigid E ^a   Parker, Karen J ^a   Reiss, Allan L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Cardiac activity; Cortisol; Eye gaze; Fragile X syndrome; Oxytocin; Social anxiety

Indexed keywords

HYDROCORTISONE; OXYTOCIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AROUSAL; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EYE TRACKING; FRAGILE X SYNDROME; GAZE; HEART RATE VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA LEVEL; SINGLE DRUG DOSE; SINUS ARRHYTHMIA; SOCIAL PHOBIA; TREATMENT DURATION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANXIETY; AROUSAL; DOUBLE-BLIND METHOD; EYE MOVEMENTS; FRAGILE X SYNDROME; HEART RATE; HORMONES; HUMANS; HYDROCORTISONE; MALE; OXYTOCIN; SALIVA; SOCIAL BEHAVIOR;

EID: 84857192799     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2011.07.020     Document Type: Article

References (56)

1. Amico J.A., Mantella R.C., Vollmer R.R., Li X. Anxiety and stress responses in female oxytocin deficient mice. J. Neuroendocrinol. 2004, 16(4):319-324.
2. Andari E., Duhamel J.R., Zalla T., Herbrecht E., Leboyer M., Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(9):4389-4394.
3. Ansseau M., Legros J.J., Mormont C., Cerfontaine J.L., Papart P., Geenen V., Adam F., Franck G. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 1987, 12(3):231-236.
4. Balin B.J., Broadwell R.D., Salcman M., el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J. Comp. Neurol. 1986, 251(2):260-280.
5. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27(7):370-377.
6. Berry-Kravis E., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J., Hutchison J., Snape M., Tranfaglia M., Nguyen D.V., Hagerman R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 2009, 46(4):266-271.
7. Berry-Kravis E., Potanos K. Psychopharmacology in fragile X syndrome - present and future. Ment. Retard. Dev. Disabil. Res. Rev. 2004, 10(1):42-48.
8. Boccia M.L., Roberts J.E. Behavior and autonomic nervous system function assessed via heart period measures: the case of hyperarousal in boys with fragile X syndrome. Behav. Res. Methods Instrum. Comput. 2000, 32(1):5-10.
9. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002, 5(6):514-516.
10. Born J., Pietrowsky R., Fehm H.L. Neuropsychological effects of vasopressin in healthy humans. Progr. Brain Res. 1998, 119:619-643.
11. Brown V., Jin P., Ceman S., Darnell J.C., O'Donnell W.T., Tenenbaum S.A., Jin X., Feng Y., Wilkinson K.D., Keene J.D., Darnell R.B., Warren S.T. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107(4):477-487.
12. Byrne E.A. Inter-Beat-Interval Editing for Heart Period Variability Analysis: An Integrated Training Program with Standards for Reliability Assessment. Unpublished Manual 1993, University of Maryland.
13. Carter S. Sex differences in the developmental consequences of oxytocin and vasopressin: implications for autism?. Paper Presented at the American College of Neuropsychopharmacology, University of Illinois at Chicago 2008.
14. Crawford D.C., Meadows K.L., Newman J.L., Taft L.F., Stanfeild M.L., Holmgreen P., Yeargin-Alsopp M., Boyle C., Sherman S.L. Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population. Am. J. Hum. Genet. 1999, 64:495-507.
15. den Boer J.A., Westenberg H.G.M. Oxytocin in obsessive compulsive disorder. Peptides 1992, 13:1083-1085.
16. Ditzen B., Schaer M., Gabriel B., Bodenmann G., Ehlert U., Heinrichs M. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol. Psychiatry 2009, 65(9):728-731.
17. Dorn L.D., Lucke J.F., Loucks T.L., Berga S.L. Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Ann. Clin. Biochem. 2007, 44(Pt 3):281-284.
18. Epperson C.N., McDougle C.J., Price L.H. Intranasal oxytocin in obsessive-compulsive disorder. Biol. Psychiatry 1996, 40(6):547-549.
19. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68(7):678-680.
20. Ferguson J.N., Young L.J., Hearn E.F., Matzuk M.M., Insel T.R., Winslow J.T. Social amnesia in mice lacking the oxytocin gene. Nat. Genet. 2000, 25(3):284-288.
21. Garber K., Smith K.T., Reines D., Warren S.T. Transcription, translation and fragile X syndrome. Curr. Opin. Genet. Dev. 2006, 16(3):270-275.
22. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 2010, 67(7):692-694.
23. Guastella A.J., Mitchell P.B., Dadds M.R. Oxytocin increases gaze to the eye region of human faces. Biol. Psychiatry 2008, 63(1):3-5.
24. Hall S.S. Treatments for fragile X syndrome: a closer look at the data. Dev. Disabil. Res. Rev. 2009, 15(4):353-360.
25. Hall S.S., DeBernardis M., Reiss A. Social escape behaviors in children with fragile X syndrome. J. Autism Dev. Disorders 2006, 36(7):935-947.
26. Hall S.S., Lightbody A.A., Huffman L.C., Lazzeroni L.C., Reiss A.L. Physiological correlates of social avoidance behavior in children and adolescents with fragile X syndrome. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48(3):320-329.
27. Hall S.S., Maynes N.P., Reiss A.L. Using percentile schedules to increase eye contact in children with fragile X syndrome. J. Appl. Behav. Anal. 2009, 42(1):171-176.
28. Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol. Psychiatry 2003, 54(12):1389-1398.
29. Hessl D., Glaser B., Dyer-Friedman J., Blasey C., Hastie T., Gunnar M., Reiss A.L. Cortisol and behavior in fragile X syndrome. Psychoneuroendocrinology 2002, 27(7):855-872.
30. Hessl D., Rivera S.M., Reiss A.L. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2004, 10(1):17-24.
31. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., Wasserman S. Oxytocin increases retention of social cognition in autism. Biol. Psychiatry 2007, 61(4):498-503.
32. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C.M., Aronowitz B.R., Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003, 28(1):193-198.
33. Irwin S.A., Christmon C.A., Grossman A.W., Galvez R., Kim S.H., DeGrush B.J., Weiler I.J., Greenough W.T. Fragile X mental retardation protein levels increase following complex environment exposure in rat brain regions undergoing active synaptogenesis. Neurobiol. Learn. Mem. 2005, 83(3):180-187.
34. Kesler S.R., Lightbody A.A., Reiss A.L. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am. J. Med. Genet. 2009, 149A(3):403-407.
35. Kiess W., Meidert A., Dressendorfer R.A., Schriever K., Kessler U., Konig A., Schwarz H.P., Strasburger C.J. Salivary cortisol levels throughout childhood and adolescence: relation with age, pubertal stage, and weight. Pediatr. Res. 1995, 37(4 (Pt 1)):502-506.
36. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V.S., Gallhofer B., Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J. Neurosci. 2005, 25(49):11489-11493.
37. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., Fehr E. Oxytocin increases trust in humans. Nature 2005, 435(7042):673-676.
38. Lightbody A.A., Reiss A.L. Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies. Dev. Disabil. Res. Rev. 2009, 15(4):343-352.
39. Mantella R.C., Vollmer R.R., Li X., Amico J.A. Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology 2003, 144(6):2291-2296.
40. Miller L.J., McIntosh D.N., McGrath J., Shyu V., Lampe M., Taylor A.K., Tassone F., Neitzel K., Stackhouse T., Hagerman R.J. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am. J. Med. Genet. 1999, 83(4):268-279.
41. Norman G.J., Cacioppo J.T., Morris J.S., Malarkey W.B., Berntson G.G., Devries A.C. Oxytocin increases autonomic cardiac control: moderation by loneliness. Biol. Psychol. 2011, 86(3):174-180.
42. O'Donnell W.T., Warren S.T. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 2002, 25:315-338.
43. Parker K.J., Buckmaster C.L., Schatzberg A.F., Lyons D.M. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 2005, 30(9):924-929.
44. Petrovic P., Kalisch R., Singer T., Dolan R.J. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J. Neurosci. 2008, 28(26):6607-6615.
45. Ranjit N., Young E.A., Raghunathan T.E., Kaplan G.A. Modeling cortisol rhythms in a population-based study. Psychoneuroendocrinology 2005, 30(7):615-624.
46. Reiss A.L., Hall S.S. Fragile X syndrome: assessment and treatment implications. Child Adolesc. Psychiatr. Clin. North Am. 2007, 16(3):663-675.
47. Silvetti M.S., Drago F., Ragonese P. Heart rate variability in healthy children and adolescents is partially related to age and gender. Int. J. Cardiol. 2001, 81(2-3):169-174.
48. Smith R. Moving molecules: mRNA trafficking in mammalian oligodendrocytes and neurons. Neuroscientist 2004, 10(6):495-500.
49. Sparrow S.S., Cicchetti D.V., Balla D.A. Vineland Adaptive Behavior Scales (Vineland-II). Parent/Caregiver Rating Form 2005, AGS Publishing, Circle Pines, MN.
50. Steward O., Schuman E.M. Compartmentalized synthesis and degradation of proteins in neurons. Neuron 2003, 40(2):347-359.
51. Tiedge H., Zhou A., Thorn N.A., Brosius J. Transport of BC1 RNA in hypothalamo-neurohypophyseal axons. J. Neurosci. 1993, 13(10):4214-4219.
52. Turner G., Webb T., Wake S., Robinson H. Prevalence of fragile X syndrome. Am. J. Med. Genet. 1996, 64(1):196-197.
53. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F.P., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65(5):905-914.
54. Williams J.R., Carter C.S., Insel T. Partner preference development in female prairie voles is facilitated by mating or the central infusion of oxytocin. Ann. N. Y. Acad. Sci. 1992, 652:487-489.
55. Windle R.J., Kershaw Y.M., Shanks N., Wood S.A., Lightman S.L., Ingram C.D. Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J. Neurosci. 2004, 24(12):2974-2982.
56. Witt D.M., Winslow J.T., Insel T.R. Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol. Biochem. Behav. 1992, 43(3):855-861.